Lyell Immunopharma (LYEL) Common Equity (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Common Equity data on file, last reported at $273.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 18.68% year-over-year to $273.7 million; the trailing twelve-month figure through Mar 2026 stood at $273.7 million (down 18.68% YoY), and the FY2025 full-year result was $248.2 million, down 35.17% from the prior year.
• Common Equity advanced to $273.7 million in Q1 2026, from $248.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $881.2 million in Q1 2022 to a low of $248.2 million in Q4 2025.
• A 5-year average of $579.1 million and a median of $603.2 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 363.81% in 2022 and plunged 47.23% in 2025, its largest moves.
• Tracing LYEL's Common Equity over 5 years: stood at $833.3 million in 2022, then dropped by 21.4% to $655.0 million in 2023, then tumbled by 41.55% to $382.8 million in 2024, then slumped by 35.17% to $248.2 million in 2025, then grew by 10.26% to $273.7 million in 2026.
• Business Quant data shows LYEL's Common Equity at $273.7 million in Q1 2026, $248.2 million in Q4 2025, and $329.1 million in Q3 2025.